Metagenomi Therapeutics (MGX) Current Assets (2023 - 2026)
Metagenomi Therapeutics (MGX) posted quarterly Current Assets of $144.6 million for Q1 2026, down 38.01% year-over-year from $233.2 million in Q1 2025, and down 12.67% quarter-over-quarter from $165.5 million in Q4 2025.
Metagenomi Therapeutics (MGX) Current Assets (2023 - 2026) Analysis & Trends
Metagenomi Therapeutics (MGX) has reported Current Assets for 4 consecutive years, with $144.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets fell 38.01% year-over-year to $144.6 million; the TTM figure through Mar 2026 stood at $144.6 million (down 38.01% YoY), while the FY2025 annual figure was $165.5 million, down 35.83% from the prior year.
- Current Assets retreated to $144.6 million in Q1 2026 per MGX's latest filing, from $165.5 million in the prior quarter.
- Across five years, Current Assets topped out at $335.6 million in Q1 2024 and bottomed at $144.6 million in Q1 2026.
- Historically, Current Assets has averaged $240.7 million across 4 years, with a median of $245.6 million in 2024.
- Annual changes were most pronounced in 2024 — Current Assets fell 7.3% — and 2026, when it slumped 38.01%.
- Metagenomi Therapeutics' Current Assets stood at $278.3 million in 2023, then retreated by 7.3% to $258.0 million in 2024, then sank by 35.83% to $165.5 million in 2025, then slipped by 12.67% to $144.6 million in 2026.
- Business Quant data shows MGX's Current Assets at $144.6 million in Q1 2026, $165.5 million in Q4 2025, and $189.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.76 Bn |
| 10 | Metagenomi Therapeutics | 46.51 Mn | 46.51 Mn | - | 124.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 124.47 Mn |
| Mar 31, 2026 | 144.56 Mn |
| Dec 31, 2025 | 165.54 Mn |
| Sep 30, 2025 | 189.82 Mn |
| Jun 30, 2025 | 211.68 Mn |
| Mar 31, 2025 | 233.20 Mn |
| Dec 31, 2024 | 257.96 Mn |
| Sep 30, 2024 | 282.29 Mn |
| Jun 30, 2024 | 307.58 Mn |
| Mar 31, 2024 | 335.64 Mn |
| Dec 31, 2023 | 278.27 Mn |